Sprycel (dasatinib), a new oral drug in Canada for chronic myeloid leukemia (CML)

There's a lot of excitement about Sprycel (dasatinib), a new oral drug in Canada for chronic myeloid leukemia (CML).

It's for patients who are resistant to or can't take other treatments...including Gleevec (imatinib).

It's a tyrosine kinase inhibitor...similar to Gleevec.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote